Amedica/US Spine and Predictive Biosciences announced licensing and distribution deals with a pair of other companies.
Salt Lake City-based spinal reconstruction implant maker Amedica/US Spine intends to distribute spinal fusion, adhesion barrier and nerve protection products based on BioDlogics’ human cellular and tissue-based products, or allografts.
The agreement allows Amedica/US Spine to grow its portfolio of osteo biologics products for spinal treatments, and are a "natural complement" to its MC2 Silicon Nitride spine spacers and spinal implants, Amedica/US Spine CEO Ben Shappley said in prepared remarks.
Lexington, Mass.-based Predictive Biosciences licensed Epigenomics AG’s (ETR:ECX) prostate cancer biomarker to use in a prostate cancer test.
Predictive had the option to license the Berlin, Germany-based cancer diagnostics company’s IP under their April 2009 agreement, in which Predictive obtained rights to develop a prostate cancer test incorporating the biomarker, according to the companies.
Based on the progress that Predictive has made in developing the cancer diagnostic, it opted to continue those rights, triggering an undisclosed license fee to Epigenomics and the potential for royalties based on the commercial success of Predictive’s test.
The companies said that a urine or tissue-based test for the biomarker, in combination with conventional histopathology, may enable a more accurate diagnosis of prostate cancer.